Sodium valproate, a histone deacetylase inhibitor, decreases the secretion of soluble Fas by human osteosarcoma cells and increases their sensitivity to Fas-mediated cell death
Purpose Effects of valproic acid (VPA), a histone deacetylase inhibitor, on the susceptibility to cell death induced by agonistic anti-Fas antibody were examined using four human osteosarcoma cell lines. Method Cell growth, secretion of soluble Fas, expression of cell-surface Fas, and sensitivity to...
Gespeichert in:
Veröffentlicht in: | Journal of cancer research and clinical oncology 2009-07, Vol.135 (7), p.879-889 |
---|---|
Hauptverfasser: | , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 889 |
---|---|
container_issue | 7 |
container_start_page | 879 |
container_title | Journal of cancer research and clinical oncology |
container_volume | 135 |
creator | Yamanegi, Koji Yamane, Junko Hata, Masaki Ohyama, Hideki Yamada, Naoko Kato-Kogoe, Nahoko Futani, Hiroyuki Nakasho, Keiji Okamura, Haruki Terada, Nobuyuki |
description | Purpose Effects of valproic acid (VPA), a histone deacetylase inhibitor, on the susceptibility to cell death induced by agonistic anti-Fas antibody were examined using four human osteosarcoma cell lines. Method Cell growth, secretion of soluble Fas, expression of cell-surface Fas, and sensitivity to Fas-mediated cell death were examined using cell proliferation assay, flow cytometry, enzyme-linked immunosorbent assay, and agonistic anti-Fas antibody, respectively. Results VPA suppressed the growth of all the four osteosarcoma cell lines and the secretion of soluble Fas from these cells. VPA showed no or slight suppressive effect on the expression of cell-surface Fas in the four osteosarcoma cell lines, but increased the sensitivity of three of four osteosarcoma cell lines to Fas-mediated cell death. Conclusion VPA enhances the susceptibility of human osteosarcoma cells to Fas-ligand-induced cell death by decreasing the secretion of soluble Fas and increasing the sensitivity to Fas-mediated cell death. |
doi_str_mv | 10.1007/s00432-008-0522-z |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_20664309</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1733349301</sourcerecordid><originalsourceid>FETCH-LOGICAL-c423t-45f4d8bb6f3ac3883ee0fe911d9442c06e62a68a1ba1f576785a1047e98e87923</originalsourceid><addsrcrecordid>eNp9UcFu1TAQjBCIvhY-gAtYSOXUgNdOnOSIKgpIlTiUnq1NsulzlcTF61R6_So-EYf3RBEHTtaOZ8bjnSx7BfI9SFl9YCkLrXIp61yWSuUPT7INrAhoXT7NNhIqyEsF5ig7Zr6VaS4r9Tw7gkYa0xjYZD-vfO-WSdzjeBc8RjoTKLaOo59J9IQdxd2ITMLNW9e66MNZgrtACWMRtyR4naLzs_CDYD8u7UjiAlm0O7FdJkw4R_KMofMTio7GkQXOfXL8y8aFZDSzi-7exZ2IfrXIJ-pdytT_Vq1x4vZF9mzAkenl4TzJri8-fT__kl9--_z1_ONl3hVKx7woh6Kv29YMGjtd15pIDtQA9E1RqE4aMgpNjdAiDGVlqrpEkEVFTU111Sh9kr3b-6a1_FiIo50crzFwJr-wVWmDhZZNIr79h3jrlzCnbFYpWUIlNSQS7Eld8MyBBnsX3IRhZ0HatUu779KmLu3apX1ImtcH46VNi3hUHMpLhNMDAbnDcQg4d47_8BSUhdRq_Yra8zhdzTcUHhP-7_U3e9GA3uJNSMbXV0qClmC0MQr0L3uCwwI</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>220517031</pqid></control><display><type>article</type><title>Sodium valproate, a histone deacetylase inhibitor, decreases the secretion of soluble Fas by human osteosarcoma cells and increases their sensitivity to Fas-mediated cell death</title><source>MEDLINE</source><source>SpringerNature Complete Journals</source><creator>Yamanegi, Koji ; Yamane, Junko ; Hata, Masaki ; Ohyama, Hideki ; Yamada, Naoko ; Kato-Kogoe, Nahoko ; Futani, Hiroyuki ; Nakasho, Keiji ; Okamura, Haruki ; Terada, Nobuyuki</creator><creatorcontrib>Yamanegi, Koji ; Yamane, Junko ; Hata, Masaki ; Ohyama, Hideki ; Yamada, Naoko ; Kato-Kogoe, Nahoko ; Futani, Hiroyuki ; Nakasho, Keiji ; Okamura, Haruki ; Terada, Nobuyuki</creatorcontrib><description>Purpose Effects of valproic acid (VPA), a histone deacetylase inhibitor, on the susceptibility to cell death induced by agonistic anti-Fas antibody were examined using four human osteosarcoma cell lines. Method Cell growth, secretion of soluble Fas, expression of cell-surface Fas, and sensitivity to Fas-mediated cell death were examined using cell proliferation assay, flow cytometry, enzyme-linked immunosorbent assay, and agonistic anti-Fas antibody, respectively. Results VPA suppressed the growth of all the four osteosarcoma cell lines and the secretion of soluble Fas from these cells. VPA showed no or slight suppressive effect on the expression of cell-surface Fas in the four osteosarcoma cell lines, but increased the sensitivity of three of four osteosarcoma cell lines to Fas-mediated cell death. Conclusion VPA enhances the susceptibility of human osteosarcoma cells to Fas-ligand-induced cell death by decreasing the secretion of soluble Fas and increasing the sensitivity to Fas-mediated cell death.</description><identifier>ISSN: 0171-5216</identifier><identifier>EISSN: 1432-1335</identifier><identifier>DOI: 10.1007/s00432-008-0522-z</identifier><identifier>PMID: 19066961</identifier><identifier>CODEN: JCROD7</identifier><language>eng</language><publisher>Berlin/Heidelberg: Berlin/Heidelberg : Springer-Verlag</publisher><subject>Antibodies - pharmacology ; Antineoplastic agents ; Biological and medical sciences ; Bone cancer ; Bone Neoplasms - pathology ; Bone Neoplasms - secretion ; Cancer Research ; Cell Death - drug effects ; Cell Proliferation - drug effects ; Cellular biology ; Diseases of the osteoarticular system ; Down-Regulation - drug effects ; Drug Evaluation, Preclinical ; Drug Synergism ; Enzyme Inhibitors - pharmacology ; fas Receptor - immunology ; fas Receptor - secretion ; Hematology ; Histone Deacetylases - pharmacology ; Histones - metabolism ; Humans ; Inhibitor drugs ; Internal Medicine ; Medical sciences ; Medicine ; Medicine & Public Health ; Oncology ; Original Paper ; Osteosarcoma - pathology ; Osteosarcoma - secretion ; Pharmacology. Drug treatments ; Solubility ; Tumor Cells, Cultured ; Tumors of striated muscle and skeleton ; Valproic Acid - pharmacology</subject><ispartof>Journal of cancer research and clinical oncology, 2009-07, Vol.135 (7), p.879-889</ispartof><rights>Springer-Verlag 2008</rights><rights>2009 INIST-CNRS</rights><rights>Springer-Verlag 2009</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c423t-45f4d8bb6f3ac3883ee0fe911d9442c06e62a68a1ba1f576785a1047e98e87923</citedby><cites>FETCH-LOGICAL-c423t-45f4d8bb6f3ac3883ee0fe911d9442c06e62a68a1ba1f576785a1047e98e87923</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00432-008-0522-z$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00432-008-0522-z$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=21540322$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19066961$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yamanegi, Koji</creatorcontrib><creatorcontrib>Yamane, Junko</creatorcontrib><creatorcontrib>Hata, Masaki</creatorcontrib><creatorcontrib>Ohyama, Hideki</creatorcontrib><creatorcontrib>Yamada, Naoko</creatorcontrib><creatorcontrib>Kato-Kogoe, Nahoko</creatorcontrib><creatorcontrib>Futani, Hiroyuki</creatorcontrib><creatorcontrib>Nakasho, Keiji</creatorcontrib><creatorcontrib>Okamura, Haruki</creatorcontrib><creatorcontrib>Terada, Nobuyuki</creatorcontrib><title>Sodium valproate, a histone deacetylase inhibitor, decreases the secretion of soluble Fas by human osteosarcoma cells and increases their sensitivity to Fas-mediated cell death</title><title>Journal of cancer research and clinical oncology</title><addtitle>J Cancer Res Clin Oncol</addtitle><addtitle>J Cancer Res Clin Oncol</addtitle><description>Purpose Effects of valproic acid (VPA), a histone deacetylase inhibitor, on the susceptibility to cell death induced by agonistic anti-Fas antibody were examined using four human osteosarcoma cell lines. Method Cell growth, secretion of soluble Fas, expression of cell-surface Fas, and sensitivity to Fas-mediated cell death were examined using cell proliferation assay, flow cytometry, enzyme-linked immunosorbent assay, and agonistic anti-Fas antibody, respectively. Results VPA suppressed the growth of all the four osteosarcoma cell lines and the secretion of soluble Fas from these cells. VPA showed no or slight suppressive effect on the expression of cell-surface Fas in the four osteosarcoma cell lines, but increased the sensitivity of three of four osteosarcoma cell lines to Fas-mediated cell death. Conclusion VPA enhances the susceptibility of human osteosarcoma cells to Fas-ligand-induced cell death by decreasing the secretion of soluble Fas and increasing the sensitivity to Fas-mediated cell death.</description><subject>Antibodies - pharmacology</subject><subject>Antineoplastic agents</subject><subject>Biological and medical sciences</subject><subject>Bone cancer</subject><subject>Bone Neoplasms - pathology</subject><subject>Bone Neoplasms - secretion</subject><subject>Cancer Research</subject><subject>Cell Death - drug effects</subject><subject>Cell Proliferation - drug effects</subject><subject>Cellular biology</subject><subject>Diseases of the osteoarticular system</subject><subject>Down-Regulation - drug effects</subject><subject>Drug Evaluation, Preclinical</subject><subject>Drug Synergism</subject><subject>Enzyme Inhibitors - pharmacology</subject><subject>fas Receptor - immunology</subject><subject>fas Receptor - secretion</subject><subject>Hematology</subject><subject>Histone Deacetylases - pharmacology</subject><subject>Histones - metabolism</subject><subject>Humans</subject><subject>Inhibitor drugs</subject><subject>Internal Medicine</subject><subject>Medical sciences</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Oncology</subject><subject>Original Paper</subject><subject>Osteosarcoma - pathology</subject><subject>Osteosarcoma - secretion</subject><subject>Pharmacology. Drug treatments</subject><subject>Solubility</subject><subject>Tumor Cells, Cultured</subject><subject>Tumors of striated muscle and skeleton</subject><subject>Valproic Acid - pharmacology</subject><issn>0171-5216</issn><issn>1432-1335</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNp9UcFu1TAQjBCIvhY-gAtYSOXUgNdOnOSIKgpIlTiUnq1NsulzlcTF61R6_So-EYf3RBEHTtaOZ8bjnSx7BfI9SFl9YCkLrXIp61yWSuUPT7INrAhoXT7NNhIqyEsF5ig7Zr6VaS4r9Tw7gkYa0xjYZD-vfO-WSdzjeBc8RjoTKLaOo59J9IQdxd2ITMLNW9e66MNZgrtACWMRtyR4naLzs_CDYD8u7UjiAlm0O7FdJkw4R_KMofMTio7GkQXOfXL8y8aFZDSzi-7exZ2IfrXIJ-pdytT_Vq1x4vZF9mzAkenl4TzJri8-fT__kl9--_z1_ONl3hVKx7woh6Kv29YMGjtd15pIDtQA9E1RqE4aMgpNjdAiDGVlqrpEkEVFTU111Sh9kr3b-6a1_FiIo50crzFwJr-wVWmDhZZNIr79h3jrlzCnbFYpWUIlNSQS7Eld8MyBBnsX3IRhZ0HatUu779KmLu3apX1ImtcH46VNi3hUHMpLhNMDAbnDcQg4d47_8BSUhdRq_Yra8zhdzTcUHhP-7_U3e9GA3uJNSMbXV0qClmC0MQr0L3uCwwI</recordid><startdate>20090701</startdate><enddate>20090701</enddate><creator>Yamanegi, Koji</creator><creator>Yamane, Junko</creator><creator>Hata, Masaki</creator><creator>Ohyama, Hideki</creator><creator>Yamada, Naoko</creator><creator>Kato-Kogoe, Nahoko</creator><creator>Futani, Hiroyuki</creator><creator>Nakasho, Keiji</creator><creator>Okamura, Haruki</creator><creator>Terada, Nobuyuki</creator><general>Berlin/Heidelberg : Springer-Verlag</general><general>Springer-Verlag</general><general>Springer</general><general>Springer Nature B.V</general><scope>FBQ</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7QP</scope><scope>7TM</scope></search><sort><creationdate>20090701</creationdate><title>Sodium valproate, a histone deacetylase inhibitor, decreases the secretion of soluble Fas by human osteosarcoma cells and increases their sensitivity to Fas-mediated cell death</title><author>Yamanegi, Koji ; Yamane, Junko ; Hata, Masaki ; Ohyama, Hideki ; Yamada, Naoko ; Kato-Kogoe, Nahoko ; Futani, Hiroyuki ; Nakasho, Keiji ; Okamura, Haruki ; Terada, Nobuyuki</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c423t-45f4d8bb6f3ac3883ee0fe911d9442c06e62a68a1ba1f576785a1047e98e87923</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Antibodies - pharmacology</topic><topic>Antineoplastic agents</topic><topic>Biological and medical sciences</topic><topic>Bone cancer</topic><topic>Bone Neoplasms - pathology</topic><topic>Bone Neoplasms - secretion</topic><topic>Cancer Research</topic><topic>Cell Death - drug effects</topic><topic>Cell Proliferation - drug effects</topic><topic>Cellular biology</topic><topic>Diseases of the osteoarticular system</topic><topic>Down-Regulation - drug effects</topic><topic>Drug Evaluation, Preclinical</topic><topic>Drug Synergism</topic><topic>Enzyme Inhibitors - pharmacology</topic><topic>fas Receptor - immunology</topic><topic>fas Receptor - secretion</topic><topic>Hematology</topic><topic>Histone Deacetylases - pharmacology</topic><topic>Histones - metabolism</topic><topic>Humans</topic><topic>Inhibitor drugs</topic><topic>Internal Medicine</topic><topic>Medical sciences</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Oncology</topic><topic>Original Paper</topic><topic>Osteosarcoma - pathology</topic><topic>Osteosarcoma - secretion</topic><topic>Pharmacology. Drug treatments</topic><topic>Solubility</topic><topic>Tumor Cells, Cultured</topic><topic>Tumors of striated muscle and skeleton</topic><topic>Valproic Acid - pharmacology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yamanegi, Koji</creatorcontrib><creatorcontrib>Yamane, Junko</creatorcontrib><creatorcontrib>Hata, Masaki</creatorcontrib><creatorcontrib>Ohyama, Hideki</creatorcontrib><creatorcontrib>Yamada, Naoko</creatorcontrib><creatorcontrib>Kato-Kogoe, Nahoko</creatorcontrib><creatorcontrib>Futani, Hiroyuki</creatorcontrib><creatorcontrib>Nakasho, Keiji</creatorcontrib><creatorcontrib>Okamura, Haruki</creatorcontrib><creatorcontrib>Terada, Nobuyuki</creatorcontrib><collection>AGRIS</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Nucleic Acids Abstracts</collection><jtitle>Journal of cancer research and clinical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yamanegi, Koji</au><au>Yamane, Junko</au><au>Hata, Masaki</au><au>Ohyama, Hideki</au><au>Yamada, Naoko</au><au>Kato-Kogoe, Nahoko</au><au>Futani, Hiroyuki</au><au>Nakasho, Keiji</au><au>Okamura, Haruki</au><au>Terada, Nobuyuki</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Sodium valproate, a histone deacetylase inhibitor, decreases the secretion of soluble Fas by human osteosarcoma cells and increases their sensitivity to Fas-mediated cell death</atitle><jtitle>Journal of cancer research and clinical oncology</jtitle><stitle>J Cancer Res Clin Oncol</stitle><addtitle>J Cancer Res Clin Oncol</addtitle><date>2009-07-01</date><risdate>2009</risdate><volume>135</volume><issue>7</issue><spage>879</spage><epage>889</epage><pages>879-889</pages><issn>0171-5216</issn><eissn>1432-1335</eissn><coden>JCROD7</coden><abstract>Purpose Effects of valproic acid (VPA), a histone deacetylase inhibitor, on the susceptibility to cell death induced by agonistic anti-Fas antibody were examined using four human osteosarcoma cell lines. Method Cell growth, secretion of soluble Fas, expression of cell-surface Fas, and sensitivity to Fas-mediated cell death were examined using cell proliferation assay, flow cytometry, enzyme-linked immunosorbent assay, and agonistic anti-Fas antibody, respectively. Results VPA suppressed the growth of all the four osteosarcoma cell lines and the secretion of soluble Fas from these cells. VPA showed no or slight suppressive effect on the expression of cell-surface Fas in the four osteosarcoma cell lines, but increased the sensitivity of three of four osteosarcoma cell lines to Fas-mediated cell death. Conclusion VPA enhances the susceptibility of human osteosarcoma cells to Fas-ligand-induced cell death by decreasing the secretion of soluble Fas and increasing the sensitivity to Fas-mediated cell death.</abstract><cop>Berlin/Heidelberg</cop><pub>Berlin/Heidelberg : Springer-Verlag</pub><pmid>19066961</pmid><doi>10.1007/s00432-008-0522-z</doi><tpages>11</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0171-5216 |
ispartof | Journal of cancer research and clinical oncology, 2009-07, Vol.135 (7), p.879-889 |
issn | 0171-5216 1432-1335 |
language | eng |
recordid | cdi_proquest_miscellaneous_20664309 |
source | MEDLINE; SpringerNature Complete Journals |
subjects | Antibodies - pharmacology Antineoplastic agents Biological and medical sciences Bone cancer Bone Neoplasms - pathology Bone Neoplasms - secretion Cancer Research Cell Death - drug effects Cell Proliferation - drug effects Cellular biology Diseases of the osteoarticular system Down-Regulation - drug effects Drug Evaluation, Preclinical Drug Synergism Enzyme Inhibitors - pharmacology fas Receptor - immunology fas Receptor - secretion Hematology Histone Deacetylases - pharmacology Histones - metabolism Humans Inhibitor drugs Internal Medicine Medical sciences Medicine Medicine & Public Health Oncology Original Paper Osteosarcoma - pathology Osteosarcoma - secretion Pharmacology. Drug treatments Solubility Tumor Cells, Cultured Tumors of striated muscle and skeleton Valproic Acid - pharmacology |
title | Sodium valproate, a histone deacetylase inhibitor, decreases the secretion of soluble Fas by human osteosarcoma cells and increases their sensitivity to Fas-mediated cell death |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-29T04%3A47%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Sodium%20valproate,%20a%20histone%20deacetylase%20inhibitor,%20decreases%20the%20secretion%20of%20soluble%20Fas%20by%20human%20osteosarcoma%20cells%20and%20increases%20their%20sensitivity%20to%20Fas-mediated%20cell%20death&rft.jtitle=Journal%20of%20cancer%20research%20and%20clinical%20oncology&rft.au=Yamanegi,%20Koji&rft.date=2009-07-01&rft.volume=135&rft.issue=7&rft.spage=879&rft.epage=889&rft.pages=879-889&rft.issn=0171-5216&rft.eissn=1432-1335&rft.coden=JCROD7&rft_id=info:doi/10.1007/s00432-008-0522-z&rft_dat=%3Cproquest_cross%3E1733349301%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=220517031&rft_id=info:pmid/19066961&rfr_iscdi=true |